Dual Therapy Approach Shows Promise for SLC6A1-Related Epileptic Encephalopathy in Preclinical Study
Researchers identified a new genetic variant in SLC6A1 that causes developmental and epileptic encephalopathy and demonstrated that combining 4-phenylbutyrate (a drug that corrects protein folding) with gene augmentation therapy rescued transporter function in cell and tissue models. The study was conducted using human cell cultures and iPSC-derived neurons, not in patients. This finding suggests a precision-medicine framework that could guide treatment strategies for patients with SLC6A1 variants, though clinical trials would be needed to confirm safety and efficacy.
Researchers at bioRxiv reported findings on a newly identified de novo SLC6A1 missense variant (p.Ala305Val) found in a patient with myoclonic-atonic epilepsy and developmental and epileptic encephalopathy. SLC6A1 encodes GAT-1, a GABA transporter whose dysfunction reduces inhibitory neurotransmitter uptake in the brain. Using protein-structure prediction algorithms, cell-based assays in HEK293T cells, and human iPSC-derived astrocytes and neurons, the team demonstrated that the A305V variant impairs protein trafficking, causing the mutant transporter to accumulate in the endoplasmic reticulum. Treatment with 4-phenylbutyrate (PBA), a clinically available chemical chaperone, partially restored transporter trafficking and GABA uptake. When combined with GAT-1 gene augmentation, the dual approach produced greater functional rescue than either intervention alone. The findings support a two-pronged precision-medicine framework for SLC6A1-related developmental and epileptic encephalopathies, though the work remains in the preclinical stage.
Limitations & open questions
The study does not report whether this dual therapy approach has been tested in animal models or whether clinical trials are planned. The limitations of the in vitro and iPSC-derived cell models compared to whole-organism disease pathophysiology are not explicitly discussed. Long-term safety and efficacy data for 4-phenylbutyrate in this specific indication are not provided.
What different sources said
- bioRxivCenter
4 Phenylbutyrate Plus Gene augmentation: A dual therapy To Rescue of SLC6A1 Variant Associated Developmental And Epileptic Encephalopathy
Related
Profilin-1 Deficiency Activates Immune Response Against Breast Cancer in Preclinical Study
Researchers found that removing the Profilin-1 protein from breast cancer cells triggers DNA damage and activates an immune pathway called STING, which recruits cancer-fighting T cells and causes tumor regression in mice. The study used CRISPR gene-editing technology to deplete Profilin-1 and observed that the resulting genomic instability paradoxically strengthens anti-tumor immunity. The findings suggest targeting Profilin-1 could be a new strategy to enhance immunotherapy effectiveness in breast cancer.
Computational Study Explores How Magnetic Fields May Affect Tomato Plant Ion Channels
Researchers used molecular dynamics simulations to investigate how static magnetic fields affect the CNGC6 ion channel in tomato plants, finding that magnetic fields may alter the channel's structure in specific ways. The study was motivated by observations that magnetic treatment of tomato seeds appears to speed germination and improve plant development, though the underlying cellular mechanisms remain unclear. The findings provide a computational foundation for future experimental work, though the authors emphasize this is a preliminary exploratory study requiring validation.
New Algorithm Simplifies Evolutionary Network Reconstruction for Hybridized Species
Researchers developed NetCS, a fast algorithm for reconstructing evolutionary networks in hybridized species that avoids expensive computational bottlenecks. The method works well when given accurate intermediate data but reveals that the real challenge in network inference lies in an earlier reconstruction step. This finding could enable phylogenetic analyses of larger datasets while identifying where future improvements are needed.